219660-71-6

Basic information

• Product Name: 5-bromo-3-(phthalimidomethyl)pyridine
• Synonyms: 5-bromo-3-(phthalimidomethyl)pyridine;2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione
• CAS NO: 219660-71-6
• Molecular Formula: C14H9BrN2O2
• Molecular Weight: 317
• Mol File: 219660-71-6.mol
• Article Data: 35

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-bromo-3-(phthalimidomethyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-3-(phthalimidomethyl)pyridine(219660-71-6)
• EPA Substance Registry System: 5-bromo-3-(phthalimidomethyl)pyridine(219660-71-6)

Safety Data

• Hazardous Substances Data: 219660-71-6(Hazardous Substances Data)

Usage

Description

5-bromo-3-(phthalimidomethyl)pyridine is a chemical compound that features a pyridine ring with a bromine atom at the 5th position and a phthalimido group attached to the 3-carbon. 5-bromo-3-(phthalimidomethyl)pyridine is recognized for its versatile reactivity and utility in organic synthesis and pharmaceutical development.

Uses

Used in Organic Synthesis:
5-bromo-3-(phthalimidomethyl)pyridine is used as a reagent for the introduction of the phthalimido group onto various molecules, facilitating the creation of new chemical entities and structures.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-bromo-3-(phthalimidomethyl)pyridine is utilized as a key intermediate in the synthesis of new drugs and medications, capitalizing on its ability to modify organic molecules and contribute to drug discovery.
Used in Material Science:
5-bromo-3-(phthalimidomethyl)pyridine also serves as a building block in the development of novel materials and chemical structures across various industrial applications, highlighting its multifaceted role in advancing chemical innovation.

Upstream product

• 908864-98-2 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine 
• 113118-81-3 5-bromopyridine-3-carbaldehyde 
• 136918-14-4 phthalimide 
• 37669-64-0 (5-bromopyridin-3-yl)methanol 

Downstream Products

• 219660-72-7 1-(5-bromopyridin-3-yl)-N-(diphenylmethylene)methanamine 
• 135124-70-8 (5-bromo-3-pyridinyl)methylamine 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR PARASITE CONTROL

The present invention relates in its broadest aspect to a compound of Formula I as provided herein, formulations comprising such a compound and corresponding uses thereof for the reduction of infestation with ectoparasites, in particular ectoparasites of the insect class, including fleas and mosquitoes and/or ectoparasites of the arachnid class, including ticks and mites, etc. Also provided herein are methods for preparing the formulations of the invention and methods for controlling ectoparasites using the compounds and/or formulations provided herein.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.